Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04277741
Other study ID # Pro9978
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date February 18, 2020
Est. completion date June 30, 2023

Study information

Verified date October 2023
Source Kansas State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the current proposal is to determine the effectiveness of long-term consumption of Fibersym® RW for improving blood lipids (including cholesterol) and body composition. The overall goal of this clinical research is to determine the potential effects that RS4 consumption may have on the prevention of obesity and obesity-related diseases. Fiber in the form of RS4 will be used for the proposed study, given that fiber has been shown to have many beneficial effects on modifiable risk factors associated with obesity-related diseases. Using a long-term randomized-controlled intervention design, blood lipids (total cholesterol, LDL-c, HDL-c, triglycerides) and body composition will be assessed. The investigators anticipate reductions in cholesterol and body fat percentage following 8-weeks of Fibersym® RW consumption.


Description:

This study will investigate the metabolic effects of daily RS4 consumption in overweight and obese adults. The investigators will recruit approximately 50 (BMI: 23-34.9kg/m2) adults ages 18-65yrs, who have elevated to borderline-high LDL-cholesterol (116-159mg/dL) to an 8-week randomized controlled intervention. Participants will be recruited in three waves of 16 participants each. Following a 7-10-day run-in where fiber intake is monitored, participants will be randomized to either the control or the RS4 group. The RS4 group will consume a high fiber bar, daily, for 8-weeks that will contain approximately 60-70% of the daily reccomended allowance of fiber. The primary outcome for this study will be fasting plasma LDL-Cholesterol (LDL-c). Secondary outcomes include body composition following daily RS4 consumption for 8-weeks. All health assessments will be conducted before the intervention begins, at the 4-week mid-point, and immediately following the 8-week intervention. Participants will fast for 10 -12 hrs. before reporting to the PAN-CRC for each testing session. The meal consumed prior to each testing session will be standardized so that it does not vary within the individual between testing sessions. Treatments. The two treatment conditions are RS4 and control. Participants will be asked to consume one nutrition bar as part of their breakfast each day with no other changes to their diet. The control group will consume one native wheat starch bar per day. The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber. This amount would likely put individuals in the recommended dietary fiber intake range according to the dietary recommended intake ( Institutes of Medicine: 14g fiber/1000 kcal). All nutrition bars will contain the same ingredients and be matched for calories; however, fiber will vary between the bars. Health assessments. The KSU Nutrition team will conduct all health assessments at each time point. Height (cm), weight (kg), and waist circumference (cm) will be measured to determine basic anthropometrics, and a dual-energy X-ray absorptiometry scan (DXA) will be used to determine body composition (body fat percentage and non-fat mass). Blood pressure (systolic and diastolic (mmHg) will be measured using a standard automated monitor. Fasting total cholesterol (TC), triglycerides (TRG), glucose, LDL-c, and HDL-c will be measured via an LDX Cholestech using a single venous blood draw for assessment. Plasma glucose and insulin will be determined via the same venous sample. Satiety will be measured during each testing session to determine how Fibersym® RW impacts feelings of fullness and hunger. Compliance Checks. To ensure compliance with consumption of the nutrition bars provided, participants will be asked to return to the PAN-CRC to return any leftover bars at the end of each intervention week (if any remain), and to pick up a new supply of their assigned bar. Participants will also be given a checklist that indicates their daily consumption of the given bars. The checklist will include options such as: I consumed the 100% of the bar, forgot to consume, consumed part of the bar (with options to check a percent of the bar consumed). To ensure that habitual dietary intake is maintained, participants will be instructed to complete a 3-day dietary record (two weekdays and 1 weekend day) prior to each testing session, allowing the investigators to determine any dietary changes that may occur during the 8-week intervention.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - BMI = 23 kg/m2 - elevated to borderline-high LDL-cholesterol (116-159 mg/dL) Exclusion Criteria: - known allergy to wheat or gluten - currently taking medication for chronic disease including anti-inflammatory, anti-hypertensive, lipid lowering, glucose controlling, or steroidal medications - taking any supplements that may affect metabolism - having anemia or a history of anemia - current smoker or a user in the past three months - currently pregnant or lactating/planning to become pregnant during the intervention - having elevated blood pressure (=130mmHg/=80mmHg) - presence of diagnosed diabetes mellitus, inflammatory disease, atherosclerotic disease, or other relevant chronic conditions that may affect metabolic processes - total cholesterol = 240mg/dL.

Study Design


Intervention

Dietary Supplement:
RS4 bar
The RS4 group will consume one nutrition bar per day formulated using Fibersym® RW containing 20g fiber.
Control bar
The control group will consume one native wheat starch bar per day.

Locations

Country Name City State
United States Physical Activity and Nutrition Clinical Research Consortium Manhattan Kansas

Sponsors (2)

Lead Sponsor Collaborator
Kansas State University MGP Ingredients, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in plasma lipids Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state Week 0, 4, and 8
Secondary Change in body composition Percent body fat as measured by DXA scan Week 0, 4, and 8
Secondary Change in BMI Weight and height will be combined to report BMI in kg/m^2 Week 0, 4, and 8
Secondary Change in homeostatic model assessment for insulin resistance (HOMA-IR) Calculated from fasting glucose and insulin levels Week 0,4, and 8
See also
  Status Clinical Trial Phase
Recruiting NCT06013163 - A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers Phase 1
Active, not recruiting NCT03843424 - Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers N/A
Not yet recruiting NCT06360536 - Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women N/A
Not yet recruiting NCT05997576 - A Study of TG103 Injection in Non-diabetic Overweight or Obesity Phase 3
Recruiting NCT04763291 - Cardiovascular and InflammAging Study N/A
Active, not recruiting NCT04399460 - The Effects of Long-term Consumption of Full-fat Dairy Products on Satiety, Body Weight and Glycemic Control N/A
Completed NCT04451824 - Examination of Circumferential Reduction N/A
Completed NCT04110717 - Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight N/A
Completed NCT05561855 - T2DM Intensity Lifestyle Intervention N/A
Active, not recruiting NCT04100200 - Berries, Inflammation, and Gut Microbiome N/A
Recruiting NCT06125964 - eMOTION Formative Study N/A
Recruiting NCT06087822 - Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21® N/A
Active, not recruiting NCT04328233 - Impact of Time-Restricted Eating on Metabolic Homeostasis, Inflammation and Oxidative Stress in Metabolic Syndrome N/A
Completed NCT06091761 - Thread Embedding Acupuncture Combined With Auricular Acupuncture for Overweight and Obesity N/A
Completed NCT04894344 - Education to Decrease in Sodium Intake Evaluated With 24 Hour Urinary Sodium Excretion (RCT) N/A
Completed NCT05713461 - Physical Exercise in Obesity for Health and Quality of Life. N/A
Not yet recruiting NCT06054698 - Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects Phase 2
Not yet recruiting NCT02823912 - Capsaicin Effect on Cytokines Profile in Dyslipidemia Phase 2/Phase 3
Completed NCT05104151 - Efficacy of a Nutritive Bar, in Reduction of Weight, Body Fat and Control of Appetite N/A
Completed NCT04786925 - Precision Nutrition Strategies for Improving the Quality of Life of Pre-senior and Senior Populations N/A